Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Mapi Pharma Files for IPO

publication date: Mar 28, 2014
Mapi Pharma of Israel, a company that develops API and intermediates, filed for a $46 million IPO on NASDAQ. The company has a China R&D operation in Nanjing’s NJUT Science and Technology Industrial Park, in addition to its facilities in Israel and Germany. Mapi develops complex APIs and improved delivery formulations for generic drugs. Its lead product is a once-monthly version of Copaxone, an MS treatment produced by Teva. More details....

Stock Symbol: (NYSE: TEVA)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital